5Leemhuis T, Wells S, Scheffold C, et al. A phase I trial of autologous cytokine-indueed killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma[J]. Biod Blood Marrow Transplant, 2005,11 (3): 181 - 187.
6Linn YC, Hui KM. Cytokine-induced killer cells: NK-like cells with cytotolytic speeifieity against leukemia [J]. Leuk Lymphoma, 2003,44(9): 1457-1462.
7Nagaraj S, Ziske C, Schmidt-Wolf IG. Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer[J]. Genet Vaccines Ther, 2004,2(1): 12.
8Verneris MR, Kornacker M, Mailander V, et al. Resistance of ex vivo expanded CD3+ CD56+ T cells to Fas-mediated apoptosis [J].Cancer Immunol Immunother, 2000,49(6):335-345.
9Zoll B, Lefierova P, Ebert O, et al. Modulation of cell surface markers on NK-like T lymphocytes by using IL-2,IL-7 or IL-12 in vitro stimulation [J]. Cytokine, 2000,12(9): 1385-1390.
10Choi BH, Kang HK, Park JS, et al. Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy [J]. J Clin Apher, 2006,21(4): 233-240.
3Sharma RK, Singh VN, Reddy HK. Thinking beyond low- density lipoprotein eholesterol: strategies to further reduce cardiovascular risk[J]. Vase Health Risk Manag, 2009, 5: 793-799.
4Schaefer JR. HDL level or HDL function as the primary target in preventive cardiology[J]. Herz, 2012, 37(1):51-55.
